The brain’s immune cells are supposed to devour the sticky amyloid plaques that accumulate in Alzheimer’s disease. In practice, those cells, called microglia, often stall out, overwhelmed by the very proteins they are meant to destroy. A study published in May 2026 in the Proceedings of the National Academy of Sciences now identifies a molecular reason for that failure and a potential fix: a single protein called PTP1B that, when blocked, appears to reawaken microglia and restore their ability to clear plaques in mice.
The research, led by Nicholas Tonks, Xiao Cen, and Mariana Ribeiro Alves at Cold Spring Harbor Laboratory, showed that genetically deleting or pharmacologically inhibiting PTP1B in Alzheimer’s mouse models reduced amyloid-beta plaque buildup and improved learning and memory. No PTP1B-targeting drug has been tested in Alzheimer’s patients, but the findings sharpen a growing preclinical case that this enzyme could be a viable therapeutic target.
How PTP1B keeps microglia from doing their job
The Cold Spring Harbor team worked with APP/PS1 mice, a widely used Alzheimer’s model that develops amyloid plaques and progressive cognitive decline. When PTP1B was removed or inhibited in these animals, they performed significantly better on learning and memory tasks and carried a lower amyloid-beta burden.
The researchers traced the effect to a specific molecular chain of events inside microglia. PTP1B directly dephosphorylates a kinase called SYK, keeping it suppressed. Remove PTP1B from the equation and SYK signaling ramps up, activating the downstream AKT-mTOR pathway. That cascade, in turn, boosts microglial phagocytosis, the process by which these immune cells engulf and break down amyloid plaques.
“This is not a broad, nonspecific immune boost,” the team emphasized in communications from Cold Spring Harbor Laboratory. The direct substrate relationship between PTP1B and SYK suggests a targeted restoration of a clearance function that Alzheimer’s pathology specifically disrupts. By tying PTP1B activity to a defined signaling cascade, the work offers a mechanistic explanation for why inhibiting this one phosphatase can translate into both reduced plaque load and better behavioral performance.
A pattern across multiple mouse models
The PNAS findings do not stand alone. In hAPP-J20 mice, a separate Alzheimer’s model, the selective PTP1B inhibitor trodusquemine rescued cognitive function, reduced neuroinflammation, and prevented neuron loss. In PLB4 mice, which carry a neuronal human BACE1 knock-in, trodusquemine treatment rescued motor learning and reduced both neuroinflammation and hyperglycemia, according to results published in Experimental Neurology.
Across three distinct mouse lines emphasizing different facets of Alzheimer’s-like pathology, the pattern holds: blocking PTP1B improves behavioral outcomes and dials down inflammatory and neurodegenerative markers. That convergence strengthens the case that PTP1B is not merely a bystander but an active contributor to disease processes, with microglial function as the key node.
Trodusquemine, also known as MSI-1436, works through an unusual mechanism first characterized in Nature Chemical Biology. Rather than competing for the enzyme’s active site, it binds to the disordered C-terminus of PTP1B, acting as an allosteric inhibitor. That structural quirk allows it to achieve selectivity for PTP1B over closely related phosphatases, a critical advantage for minimizing off-target effects.
Where this fits in the Alzheimer’s drug landscape
The Alzheimer’s field has been reshaped in recent years by the approval of anti-amyloid antibodies such as lecanemab (Leqembi) and donanemab (Kisunla), which target amyloid plaques from outside the cell by binding to them and flagging them for removal. PTP1B inhibitors would work from the opposite direction, boosting the brain’s own immune cells to clear plaques more aggressively from within.
In theory, the two approaches could complement each other. Anti-amyloid antibodies have shown modest but measurable slowing of cognitive decline in clinical trials, though they carry risks of brain swelling and microbleeds. A drug that enhances microglial clearance without directly provoking an antibody-mediated inflammatory response could offer a different risk-benefit profile, or potentially augment existing therapies. That possibility, however, remains entirely speculative until human data exist.
Trodusquemine itself has been tested in people, but only for metabolic conditions. A Phase 1 trial targeting obesity was conducted years ago by the now-defunct Genaera Corporation, providing some preliminary safety and pharmacokinetic data. Those results do not address whether the compound can reach relevant targets in the brain at tolerable doses over longer treatment periods.
On the development side, the biotech company DepYmed presented an update on its lead PTP1B inhibitor candidate, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting. That presentation focused on Rett syndrome, not Alzheimer’s, and no public update on an Alzheimer’s-specific clinical timeline has appeared since. Whether DPM-1003 or a related compound will enter Alzheimer’s trials depends on funding, regulatory strategy, and preclinical data packages that remain undisclosed.
The gaps that still need closing
The most significant limitation is the one that has haunted Alzheimer’s research for decades: mice are not people. Rodent models replicate certain features of the disease, particularly amyloid plaque formation, but they do not capture the full complexity of human neurodegeneration. Drugs that clear plaques and restore cognition in mice have failed repeatedly in clinical trials, often because human Alzheimer’s involves additional pathologies such as tau tangles, vascular damage, slower progression, and far greater biological variability.
Long-term safety data for PTP1B inhibition in the brain are also sparse. PTP1B plays roles in insulin signaling, leptin responses, immune regulation, and other pathways throughout the body. Blocking it systemically could produce off-target effects that short-duration mouse studies would miss, including potential impacts on metabolism, infection susceptibility, or tumor surveillance, particularly concerning in older adults who often manage multiple chronic conditions.
The mechanistic link between PTP1B inhibition and the SYK-AKT-mTOR signaling cascade, while clearly demonstrated in the PNAS paper, has not yet been independently replicated by other laboratories. Confirmation in additional models and species will be important to rule out artifacts of specific experimental conditions. Researchers will also need to understand how this pathway interacts with other microglial programs implicated in Alzheimer’s, including TREM2-dependent responses and interferon signaling.
Timing presents another challenge. Most mouse experiments to date began treatment before or around the onset of overt symptoms, a scenario that rarely mirrors clinical reality, where patients typically present with established cognitive decline. Whether PTP1B inhibition can reverse advanced pathology or primarily slows early progression is unknown. Designing trials that distinguish prevention from treatment effects will require careful selection of participants, endpoints, and biomarkers.
Promising biology, a long road to the clinic
More than 6 million Americans live with Alzheimer’s disease, a number projected to nearly double by 2050, according to the Alzheimer’s Association. Even with newly approved antibody therapies, the need for additional treatment approaches remains urgent. PTP1B inhibitors represent a fundamentally different strategy: rather than deploying an external agent to tag plaques for destruction, they aim to unlock the brain’s own immune machinery.
The Cold Spring Harbor study adds a critical piece to that puzzle by mapping the precise signaling route through which PTP1B suppresses microglial clearance. Combined with consistent results across three separate mouse models, the preclinical case is among the stronger ones in early-stage Alzheimer’s research.
But preclinical promise and clinical reality remain separated by years of work. Rigorous replication, long-term toxicology studies, blood-brain barrier penetration data, and well-designed human trials all stand between these mouse results and a treatment that could reach patients. For now, PTP1B inhibitors belong in the category of compelling experimental leads, not imminent therapies. The science is real. The question is whether it will survive the jump from the laboratory to the human brain.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
